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Azole fungicides show a broad antifungal
activity and are used either to prevent fungal
infections or to cure an infection. Therefore,
they are important tools in integrated agri-
cultural production. According to their
chemical structure, azole compounds are
classiﬁed into triazoles and imidazoles; how-
ever, their antifungal activity is due to the
same molecular mechanism. The cell mem-
brane assembly of fungi and yeast is dis-
turbed by blocking the synthesis of the
essential membrane component ergosterol.
This fundamental biochemical mechanism is
the basis for the use of azole fungicides in
agriculture and in human and veterinary
antimycotic therapies. The enzyme involved
is sterol 14α-demethylase, which is found in
several phyla. In mammals, it converts lanos-
terol into the meiosis-activating sterols
(MAS). These precursors of cholesterol have
been recently discovered to modulate the
development of male and female germ cells.
Aromatase is another target enzyme of
azole compounds. In steroidogenesis, it con-
verts androgens into the corresponding estro-
gens. The importance of androgens and
estrogens for the development of reproductive
organs, for fertility, and in certain sex steroid-
dependent diseases is well known. Therefore,
azole compounds can be directed against aro-
matase to treat estrogen-responsive diseases.
The broad use of biologically active com-
pounds in human therapy as well as in non-
human applications may involve some risks,
as exemplified by emerging antibiotic resis-
tance. In agriculture, fungi and yeast are well
known to develop resistance to azoles, and
some molecular mechanisms of resistance
development have been described (Joseph-
Horne and Hollomon 1997). The signifi-
cance of the agricultural azole resistance for
human clinical antimycotic therapies has
been recently discussed in Europe, but is not
clariﬁed yet (Hof 2001).
The antifungal properties of azoles and the
issue of azole resistance in agriculture and med-
icine, however, are not the topics of this review.
Our focus is rather on the increasing evidence
for adverse effects of high doses of azole fungi-
cides on the mammalian steroid metabolism.
Use of Azoles
Azole fungicides in agriculture. According to
the U.S. Environmental Protection Agency
(EPA), in 1997 approximately 244,000 and
37,000 tons of fungicides were sold world-
wide and in the United States, respectively
(U.S. EPA 1999). Unfortunately, precise data
on the proportion of azole fungicides are not
available. In Switzerland, nearly 40 tons of
azoles are sold per year, which is approxi-
mately 5% of active ingredients in fungicides.
Maximum residue limits (MRLs) of pesti-
cides approved in Switzerland are listed in the
Swiss Ordinance on Foreign Substances and
Toxic Components in Foodstuffs (Federal
Authorities of the Swiss Confederation
2000). Within the group of the azole fungi-
cides, currently 16 triazoles (bitertanol,
cyproconazole, difenoconazole, epoxicona-
zole, fluquinconazole, flusilazole, flutriafol,
hexaconazole, metconazole, myclobutanil,
penconazole, propiconazole, tebuconazole, tri-
adimefon, triadimenol, triticonazole) and
three imidazoles (imazalil, prochloraz, and tri-
flumizole) are listed. Additionally, there are
triazoles with nonfungicidal applications (e.g.,
azocyclotin is used as an acaricide, paclobutra-
zole as a growth regulator, carfentrazone as a
herbicide, and isazophos as an insecticide). An
imidazole moiety is also found in the
chloroacetanilid herbicide metazachlor.
Identity, chemical structure and physico-
chemical and other properties of azole fungi-
cides, as well as their metabolic pathways in
animals, plants and soils, are described else-
where (Roberts and Hutson 1999; Tomlin
1997).
Azoles in treatment of human diseases. In
the treatment of systemic and dermal mycoses,
azoles play a pivotal role (Bodey 1992;
Georgopapadakou 1998). They show signiﬁ-
cantly fewer side effects in comparison with
other antimycotics such as amphotericin B,
they can be applied after the emergence of
resistance to other antimycotics (Espinel-
Ingroff 1997), and they are inexpensive.
Individual azole compounds are found in
many different antimycotic formulations. In
Switzerland, three triazoles (terconazole, itra-
conazole, fluconazole) and eight imidazoles
(clotrimazole, miconazole, econazole, ketocona-
zole, tioconazole, isoconazole, oxiconazole, and
fenticonazole) are in use (Documed AG 2002).
Another significant application of azoles
is the management of advanced estrogen-
responsive breast tumors in postmenopausal
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Research Reviewwomen (Murray 2001; Santen and Harvey
1999). In these women, the estrogen levels
dramatically decrease due to the lack of syn-
thesis in the ovaries. At this time point, the
adipose tissue becomes the main site of estro-
gen production. In patients suffering from
breast cancer, the tumor and the surrounding
tissues express aromatase and hence produce
estrogen as well (Santner et al. 1997). This
local production can substantially support
the growth of estrogen-responsive tumors,
and treatment with azole compounds (letro-
zole, anastrozole, vorozole, or fadrozole) sup-
presses estrogen production dramatically in
these patients. Consequently, tumor growth
can be blocked, and sometimes even remis-
sion occurs (Bhatnagar et al. 2001; Bisagni et
al. 1996; de Jong et al. 1997; Dixon et al.
2000). In Switzerland, currently the two tria-
zoles letrozole and anastrozole are in use at
recommended doses of 2.5 mg/day or 1
mg/day, respectively (Documed AG 2002),
partially replacing the classical nonsteroidal
antiestrogen tamoxifen. 
In a clinical trial, anastrozole was also
effective in the treatment of estrogen-depen-
dent endometriosis (Takayama et al. 1998).
Furthermore, letrozole was used to treat boys
with delayed puberty and short stature to
induce growth (Wickman et al. 2001). The
rationale behind this treatment is that azoles
inhibit estrogen-dependent bone maturation.
This leads to a delayed closure of the epiphysial
growth plates and thereby allows growth.
These examples demonstrate the increasing
importance of azole compounds in sex-steroid
hormone-dependent diseases.
Target Enzymes of Azoles in
Steroidogenesis
In this section we review the molecular char-
acteristics and the involvement in steroidoge-
nesis of both the sterol 14α-demethylase
(encoded by the CYP51 gene) and the aro-
matase (encoded by the CYP19 gene), and we
summarize the results of inhibition studies
with azole compounds.
Sterol 14α-demethylase. Sterol 14α-
demethylase is a member of the superfamily of
heme-containing cytochrome P450 enzymes
involved in metabolism of endogenous and
xenobiotic substances. The antifungal effect of
azoles is due to inhibition of sterol 14α-
demethylase in fungi and yeast, thereby block-
ing the biosynthesis of ergosterol (Espinel-
Ingroff 1997; Georgopapadakou 1998;
Joseph-Horne and Hollomon 1997). The
subsequent lack of ergosterol is detrimental
because ergosterol is an essential sterol compo-
nent in the membranes of fungi and yeast.
Sterol 14α-demethylase is not only
expressed in fungi and yeast but is also found
in many other species ranging from bacteria to
mammals. The DNA sequences encoding
sterol 14α-demethylase of many fungi and
yeast are known, as well as the sequences of
mice, rats, pigs, and humans (Debeljak et al.
2000; Kojima et al. 2000; Nitahara et al. 1999;
Stromstedt et al. 1996). On the protein level,
the amino acid sequences are highly conserved
along the phylogenetic tree. This fact is con-
sidered by many authors as an indication of
the pivotal role of sterol 14α-demethylase in
all organisms. The homology of the amino
acid sequence level between rats and humans
is 93% and 40% between fungi and humans
(Stromstedt et al. 1996). In humans, the
sterol 14α-demethylase is expressed in many
different tissues (Raucy et al. 1991).
The common linear precursor squalene is
converted to the basic sterol structures in
fungi, yeast, plants, and animals by complex
reactions, including cyclizations. These sterols
are the substrates of the sterol 14α-demethy-
lase (Figure 1). In all species, the sterol 14α-
demethylase oxidatively demethylates C-14 of
these basic sterols. The reaction has been stud-
ied in detail and it was shown to closely
resemble the demethylation reaction at C-10
catalyzed by aromatase (Shyadehi et al. 1996).
In fungi, the sterol 14α-demethylase reaction
leads to an important precursor of ergosterol.
In plants, the sterol 14α-demethylase reaction
metabolizes obtusifoliol and provides precur-
sors for biosynthesis of phytosterols. In ani-
mals, the sterol 14α-demethylase reaction is
part of the metabolic pathway leading to
biosynthesis of cholesterol. Cholesterol in turn
is the substrate for the production of many
other sterols (e.g., the sex steroid hormones).
In more detail, C-14 demethylation of lanos-
terol in animals produces the follicle fluid
meiosis-activating sterol (FF-MAS), which is
further metabolized to the testis meiosis-acti-
vating sterol (T-MAS). Otherwise, if lanos-
terol is reduced by the sterol ∆24-reductase to
24,25-dihydrolanosterol before demethyla-
tion, the resulting metabolites are MAS-412
and MAS-414, respectively (Figure 2; Byskov
et al. 1995).
Although the speciﬁc inhibition of fungal
sterol 14α-demethylase by competitive,
reversible binding to the heme moiety of the
enzyme is the intended effect of azoles in agri-
culture and clinical antifungal treatments (Ji
et al. 2000; Podust et al. 2001; Yoshida and
Aoyama 1987), some azole compounds are
not very speciﬁc in this respect. Clotrimazole,
miconazole, sulconazole, tioconazole, and
ketoconazole were shown to inhibit many dif-
ferent P450 enzymes (Zhang et al. 2002).
The inhibition of sterol 14α-demethylase
by azoles, expressed as the half maximal
inhibitory concentration (IC50), depends on
the azole derivative and to a lesser extent on
the source of sterol 14α-demethylase (Van
den Bossche et al. 1987). For example, the
IC50 values for triadimenol and tebuconazole
on the sterol 14α-demethylase prepared from
the phytopathogen fungus Ustilago maydis are
0.07 and 0.05 nM, respectively, whereas for
sterol 14α-demethylase prepared from the
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Figure 1. Biosynthesis of phytosterols, ergosterol, and mammalian sex steroid hormones. Arrows indicate
one or more enzymatic steps. Reactions catalyzed by sterol 14α-demethylase (1) and aromatase (2) are
indicated.
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C-14 demethylated phytosterolsplant Sorghum bicolor, the IC50 values are only
slightly higher (0.24 and 0.16 nM, respec-
tively; Lamb et al. 2001). Ketoconazole and
itraconazole, respectively, exhibited IC50 val-
ues of 60 and 80 nM on Candida albicans
sterol 14α-demethylase and of 580 and 610
nM on human sterol 14α-demethylases, both
enzymes heterologously expressed in yeast
(Lamb et al. 1999). For ketoconazole, itra-
conazole, and ﬂuconazole, IC50 values of 180
nM, 330 nM, and 170 µM, respectively, were
reported for rat sterol 14α-demethylase
expressed in Escherichia coli (Nitahara et al.
1999). In crude extracts of yeast, the sterol
14α-demethylase is inhibited by flusilazole
approximately 100 times more efﬁciently than
in crude cell-free extracts from rat liver
(Trzaskos and Henry 1989). This difference
was nearly abolished upon further puriﬁcation
of the enzymes. According to the authors, the
differences in the crude extracts are due to dif-
ferent contents in other azole-susceptible
P450 enzymes that may scavenge the azoles. 
In conclusion, the direct comparison of
the IC50 values from different studies is ham-
pered by considerable variations in the study
designs and test materials used, such as
enzyme purity.
Aromatase. Another important P450
enzyme involved in the steroidogenesis is aro-
matase. Like sterol 14α-demethylase, aro-
matase catalyzes the oxidative demethylation
of sterols. In contrast to sterol 14α-demethy-
lase, which has several substrates in different
phyla, aromatase demethylates C10 and
specifically converts androstenedione and
testosterone, resulting in estrone and estra-
diol, respectively (Figure 1). However, other
nonsteroid substrates of the aromatase, such
as 7-ethoxycoumarin are also known (Toma
et al. 1996). The aromatase coding DNA
sequences of several animals (Hickey et al.
1990; McPhaul et al. 1988; Tanaka et al.
1992; Trant 1994) and humans (Evans et al.
1986; Means et al. 1989; Toda and Shizuta
1993) have been published. On the protein
level, the amino acid sequence homology
between aromatase from fish and humans is
about 50% (Trant 1994) and between rats
and humans is about 78% (Hickey et al.
1990). In mammals, aromatase is mainly
expressed in the brain and the gonads, but it
is also found in placental, adipose, and bone
tissue (Conley and Hinshelwood 2001).
The physiologic balance between different
sex steroid hormones is crucial for the devel-
opment, maintenance, and function of the
reproductive system as well as for the differ-
entiation of the sexual phenotype during
ontogeny. Estrogens (estrone and estradiol)
are products of the androgens (androstene-
dione and testosterone), and the reaction is
catalyzed by aromatase. In mammals, differ-
entiation of the male phenotype depends not
only on testosterone but also on estradiol
generated from testosterone by neuronal aro-
matase in central nervous system. Therefore,
disturbances in aromatase expression and/or
changes in its catalytic activity are expected to
exhibit negative effects on reproduction para-
meters. In fact, in transgenic male mice over-
expressing aromatase in the testis, the serum
estradiol level is increased (Fowler et al.
2000). Half of these animals were infertile
and had larger testes and a significantly
increased incidence of Leydig cell tumors in
testes. In male and female aromatase knock-
out mice (ArKO), the estradiol levels are
below detection limits in both sexes. In
males, the testosterone levels are elevated in
the ﬁrst 12–14 weeks only, and female ArKO
mice showed a pronounced increase in testos-
terone levels (Fisher et al. 1998; Robertson et
al. 1999).
Aromatase can be inhibited competitively
and reversibly by azole compounds, as seen
with sterol 14α-demethylase. The IC50 values
of the azole fungicides prochloraz, imazalil,
propiconazole, triadimenol, and triadimefon
on microsomal aromatase from human pla-
centa were 0.04, 0.34, 6.5, 21, and 32 µM,
respectively (Andersen et al. 2002; Vinggaard
et al. 2000). In a rat ovary aromatase assay,
the therapeutic drugs anastrozole, fadrozole,
and letrozole exhibited IC50 of 0.025, 0.007
and 0.007 µM, respectively (Odum and
Ashby 2002). Not only azoles but also nat-
ural plant constituents such as ﬂavonoids are
able to significantly inhibit the aromatase
(Jeong et al. 1999).
Biological Effects of Azole
Compounds
Based on the inhibitory activity of azoles on
key enzymes involved in sex steroid hormone
synthesis, it is likely that effects on fertility,
sexual behavior, and reproductive organ
development will occur depending on dose
level and duration of treatment of laboratory
animals. Therefore, we reviewed the toxicology
monographs of the Joint FAO/WHO (Food
and Agriculture Organization/World Health
Organization) Meeting on Pesticide Residues
(JMPR) on some azole fungicides by focusing
on effects that might be induced by disturbed
steroidogenesis (Appendix).
Role of sterol 14α-demethylase in germ cell
development. As discussed above, in mammals,
sterol 14α-demethylase either directly converts
lanosterol into FF-MAS or, after preceding
reduction of lanosterol by sterol ∆24-reductase
into MAS-412. Sterol ∆14-reductase then con-
verts FF-MAS in T-MAS and MAS-412 in
MAS-414 (Figure 2). These metabolites of
lanosterol have been regarded only as precur-
sors of cholesterol without any biological
function in animals. This view dramatically
changed recently with the observation that
FF-MAS isolated from human follicle fluid
and T-MAS isolated from bull testis as well as
the MAS-412 and MAS-414 induced resump-
tion of meiosis in cultivated mouse oocytes
(Byskov et al. 1995).
In rats, expression of sterol 14α-demethy-
lase in postmeiotic spermatids is signiﬁcantly
higher than in premeiotic spermatids
(Stromstedt et al. 1998) and is restricted to
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Figure 2. Biosynthesis of MAS. Reactions catalyzed by sterol 14α-demethylase (1) are indicated.
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(Majdic et al. 2000). In the developing rat
testis, high levels of T-MAS were found.
These increased T-MAS levels were due to the
selective up-regulated expression of cholesto-
genic genes, namely the pre-MAS genes such
as sterol 14α-demethylase, and down-regu-
lated post-MAS genes (Tacer et al. 2002). In
the human hepatoma cell line HepG2 and in
rat testes, progestins inhibited the cholesterol
biosynthesis, and consequently the levels of
FF-MAS and T-MAS were increased
(Lindenthal et al. 2001). In mouse oocytes, in
vitro resumption of meiosis was induced by
the speciﬁc blocking of the sterol ∆14-reduc-
tase, and hence the FF-MAS level was elevated
(Leonardsen et al. 2000). In another study,
only denuded oocytes responded to higher
FF-MAS levels but not cumulus-cell–enclosed
oocytes (Downs et al. 2001). Resumption of
meiosis in vitro by increased FF-MAS levels
was also observed in human oocytes (Cavilla
et al. 2001). The biological signiﬁcance of the
MAS and their implications on fertilization
were recently reviewed (Byskov et al. 2002;
Rozman et al. 2002). However, other studies
failed to show these pronounced effects of
MAS on oocytes (Tsafriri et al. 1998, 2002;
Vaknin et al. 2001). 
Although the detailed function of the
MAS is not fully understood yet, the existing
studies indicate an important role of these
sterols in the development of testis and sper-
matids and possibly also an impact on the
oocyte development.
Effects induced by aromatase inhibition.
Azole fungicides described in the JMPR
monographs (see Appendix) and azole com-
pounds used in the management of breast
cancer share some common effects in vitro
and in vivo.
The potential of azoles to lower estradiol
levels and to delay ovulation in rats has been
known for several years as is exemplified by
an isomer of ﬂutriafol (Middleton et al. 1986;
Milne et al. 1987). 
Although on the molecular level (e.g.,
IC50 values) no profound species differences
are seen, distinct effects are observed in labo-
ratory animals after azole treatment. In dogs,
exposure to letrozole induced histopathologic
changes in the testis, whereas in rats no such
effects were observed (Walker and Nogues
1994). In female rats, letrozole (Sinha et al.
1998) and vorozole (De Coster et al. 1990)
considerably lowered estrogen levels and
reduced uterus weights. In a mouse MCF-7
xenograft model, tumor growth was effec-
tively inhibited by letrozole (Lee et al. 1995).
The same effect on rat mammary tumor
growth was seen with letrozole and a deriva-
tive thereof, in addition to a prominent
reduction of estradiol levels and uterus
weights (Schieweck et al. 1993). In male
cynomolgus monkeys, vorozole lowered the
estradiol levels (Tuman et al. 1991) and in
quails (Foidart et al. 1994) and in female
musk shrews (Rissman et al. 1996) it changed
sexual behavior. The treatment of growing
male rats with vorozole impaired skeletal
development and the mineralization of bones
(Vanderschueren et al. 1997).
In European pond turtles (Belaid et al.
2001) and in whiptail lizards (Wennstrom
and Crews 1995), letrozole affected sex deter-
mination, as did fadrozole in chickens and
turkeys (Burke and Henry 1999). Juvenile
sexually undifferentiated fathead minnows
were shown to masculinize when exposed to
fadrozole in combination with methyltestos-
terone (Zerulla et al. 2002). In another study
on fathead minnows exposed to fadrozole,
reduced brain aromatase activity was accom-
panied by reduced estradiol and vitellogenin
levels, and a decrease in mature oocytes and
an increase in sperms in testes was observed
(Ankley et al. 2002). In nonhuman primates,
it was shown that fadrozole, letrozole, and a
derivative of letrozole inhibited the aromatase
(Shetty et al. 1997, 1998). Although in
female animals the estrogen levels were signif-
icantly decreased, the development of follicles
seemed normal but the animals did not
become pregnant. In the males, the treatment
resulted in elevated testosterone levels, and
the production of spermatocytes was signiﬁ-
cantly reduced within the first 30 days of
treatment. In contrast, within the ﬁrst 90 or
120 days of treatment, in ArKO mice the
spermatogenesis seemed normal and the sper-
matozoa in vitro were as fertile as the wild-
type spermatozoa (Fisher et al. 1998;
Robertson et al. 1999). Yet there were fewer
litters with these males. The authors suggest
alterations in mounting behavior as being the
reason for this discrepancy (Robertson et al.
2001). Additionally, elevated prostate weights
without malignant changes were observed in
ArKO male mice (McPherson et al. 2001).
Many of the effects described can be seen
as the result of a disturbed balance of andro-
gens and estrogens, provoked either by chem-
ically blocking aromatase or by the lack of a
functional aromatase in the case of knockout
animals. In animal studies to investigate the
chemical blockage of the aromatase by azoles,
it cannot be excluded that the sterol 14α-
demethylase also was blocked. Interpretations
of these results therefore should include not
only changed androgen and estrogen levels
but also a disturbed balance of MAS levels.
Summary
Several azole compounds were shown to inhibit
the aromatase and to disturb the balance of
androgens and estrogens in vivo. In fact, the
clinical use of azole compounds in estrogen-
dependent diseases is based on this effect.
Additionally, azole antifungals developed to
inhibit the sterol 14α-demethylase of fungi
and yeast in agriculture and medicine are also
inhibiting aromatase. Therefore, these anti-
fungals may unintentionally disturb the bal-
ance of androgens and estrogens. Until now,
it is not clear whether this effect is compen-
sated by an increased expression of aromatase
or by other unknown mechanisms.
The actual target enzyme of azole antifun-
gals, the fungal sterol 14α-demethylase, is
expressed in many species including humans,
and it is highly conserved through evolution.
Hence, it seems reasonable to assume that
most of the azole antifungals used in agricul-
ture and medicine as well as azoles used in
management of breast cancer also act as
inhibitors on human sterol 14α-demethylase
to an unknown extent. Unfortunately, there
are few studies on the inhibition of mam-
malian sterol 14α-demethylases by azole
compounds.
The impact of inhibition of the mamalian
sterol 14α-demethylase on the cholesterol
pool is not clear. Because dietary cholesterol
may compensate disturbances in cholesterol
levels, the cholesterol pool might be not a
very sensitive parameter for sterol 14α-
demethylase inhibition. However, spermato-
genesis and oogenesis are in part controlled
by MAS, and the conversion of lanosterol to
MAS exclusively relies on sterol 14α-
demethylase activity. The data available pro-
vide good evidence that azoles directed
against the ergosterol biosynthesis of fungi
and yeast have the potential to inﬂuence the
levels of FF-MAS, T-MAS, androgens, and
estrogens in animals and humans.
To our knowledge, structure–activity rela-
tionships of azoles with respect to their ability
to discriminate between sterol 14α-demethy-
lase and aromatase have hardly been investi-
gated. There is also a lack of data on enzyme
regulation of sterol 14α-demethylase and aro-
matase after azole exposure and on the puta-
tive impact of dietary cholesterol. Inhibition
of other P450 enzymes by azoles is even less
investigated.
The toxicologic proﬁles of individual azole
fungicides, as summarized in the Appendix,
provide evidence for endocrine effects. In fact,
many of these fungicides have effects on
prostate, testis, uterus, and ovaries as well as
on fertility, development, and sexual behavior.
The current database does not allow us to
establish causal relationships of these effects
with inhibition of sterol 14α-demethylase
and/or aromatase, but the overall view
strongly suggests a connection with disturbed
steroidogenesis.
Based on the clear effects on steroidogenic
enzymes in vitro, animal studies should be
performed with concomitant analysis of
androgen, estrogen and MAS levels and
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sterol 14α-demethylase, mammalian sterol
14α-demethylases, and aromatase are clearly
necessary. 
The Endocrine Disrupter Screening and
Testing Advisory Committee (EDSTAC) of
the U.S. EPA has recommended the aro-
matase inhibition assay as one of the possible
testing system to identify endocrine disrupters
(EDSTAC 1998). Since the publication of the
EDSTAC report in 1998, recent studies on
the impact of MAS on spermatogenesis and
oogenesis have been published and, as a conse-
quence, sterol 14α-demethylase should also be
considered as a candidate testing system for
identifying endocrine disrupters.
Exposure estimates based on residue values
from supervised ﬁeld trials are performed by
JMPR. These estimates indicate that the aver-
age daily intake of individual azole fungicides
is approaching at most a very low percentage
of the acceptable daily intake (ADI) estab-
lished by the JMPR. According to residue data
from food random sampling, the MRLs are
hardly ever exceeded. Nevertheless, several
azole fungicides are found in the candidate list
of putative endocrine disrupters within the
European Union Community strategy for
endocrine disrupters (European Commission
DG ENV 2002).
In conclusion, azole fungicides interact
with several P450 enzymes in different species
and have the potential to affect the endocrine
system by interacting with steroidogenesis.
Due to the knowledge of the common mecha-
nism on steroidogenesis in target organisms
and mammalians, we suggest that azole fungi-
cides should be considered as a group when
MRLs are allocated. It will be the challenge to
design more speciﬁc inhibitors of fungal sterol
14α-demethylases that do not affect animal
sterol 14α-demethylases and aromatases.
Review | Azole fungicides affect steroidogenesis
Environmental Health Perspectives • VOLUME 111 | NUMBER 3 | March 2003 259
Appendix
Usually, the hazard assessments of pesticides
by the JMPR are based on data of in vitro and
animal studies providing no observable effect
levels (NOEL) for delineation of individual
ADIs in humans. Based on the ADI and
residue levels in plants after application of rec-
ommended use levels, MRLs are allocated to
individual foods by the authorities.
In vivo studies of some azole fungicides
are summarized below with special focus on
effects putatively connected to disturbed
steroidogenesis. In the allocation procedure
for an ADI by the JMPR, these effects are
included.
Bitertanol was evaluated by the JMPR in
1998 (FAO/WHO 1999). An ADI of 0–0.01
mg/kg body weight (bw) was allocated based
on a NOEL of 1 mg/kg bw in a three-genera-
tion rat study and reduced pup survival rates
at 5 mg/kg bw. Histopathologic changes in
the adrenal glands of dogs and rats were seen
at 1.2 and ≥ 81 mg/kg bw, respectively. In
dogs, at ≥ 5 mg/kg bw, cataracts and reduced
prostate weight with histopathologic changes
were seen. In male rats, at ≥ 300 mg/kg bw,
the relative testis weights were increased, and
in females, the absolute ovary and adrenal
weights were decreased with histopathologic
changes. At the maternotoxic level of 100
mg/kg bw, rat fetuses showed effects such as
cleft palate and hydrocephalus.
Cyproconazole induced cleft palate,
hydrocephalus, and hydronephroses in rat
embryos after treatment of the dams with
20 mg/kg bw (the lowest dose tested); ≥ 50
mg/kg bw increased incidences of resorp-
tions and dead fetuses were observed
(Machera 1995).
Flusilazole was evaluated by the JMPR
in 1995 (FAO/WHO 1996). An ADI of
0–0.001 mg/kg bw was allocated based on a
NOEL of 0.14 mg/kg bw in a 1-year dog
study. At ≥ 0.7 mg/kg bw, effects on the liver
of the dogs were observed. In a 14-day rat
study, the levels of testosterone and estradiol
were reduced at ≥ 20 mg/kg bw. In isolated
Leydig cells, the IC50 for testosterone produc-
tion was 3.5 µM for ﬂusilazole and 1 µM for
ketoconazole. In a 2-year rat study, 31 mg/kg
bw ﬂusilazole induced Leydig cell tumors of
the testis; ﬂusilazole was fetotoxic and embry-
otoxic at ≥ 9 mg/kg bw in a developmental
study. Toxicity to the dams was observed at
≥ 27 mg/kg bw. In in vitro teratogenicity
assays with rat embryos, changes at the
branchial apparatus were seen at 6.25 µM
(Menegola et al. 2001).
Hexaconazole was evaluated by the
JMPR in 1990 (FAO/WHO 1991). An ADI
of 0–0.005 mg/kg bw was allocated based on
a NOEL of 0.47 mg/kg bw in a 2-year rat
study. At 4.7 ≥ mg/kg bw an increased inci-
dence of Leydig cell tumors in testis was
observed. In a 90-day rat study, histopatho-
logic changes were observed in the adrenal
glands at ≥ 2.5 mg/kg bw, and reduced testis
and adrenal weights were observed at 250
mg/kg bw. In rats, hexaconazole was fetotoxic
at ≥ 25 mg/kg bw. Isolated rat Leydig cells
showed reduced testosterone and increased
progesterone production on exposure to
hexaconazole (0.1–30 µM).
In a 29-day mouse study, lack of corpora
lutea and smaller ovaries were observed in
females and histopathologic changes in the
testis and epididymis and enlarged adrenals
were observed in males at ≥ 14 mg/kg bw.
In a 90-day dog study, weights of ovaries
and testes were reduced at ≥ 125 mg/kg bw.
Imazalil was evaluated by the JMPR in
2000 (FAO/WHO 2001). In a 1-year dog
study, an ADI of 0–0.03 mg/kg bw was
allocated based on a NOEL of 2.5 mg/kg
bw and effects on body weight, the liver,
and clinical symptoms at 20 mg/kg bw. At a
dose range of 5–20 mg/kg bw imazalil was
fetotoxic in rats, mice, and rabbits.
Myclobutanil was evaluated by the
JMPR in 1992 (FAO/WHO 1993a). An
ADI of 0–0.03 mg/kg bw was allocated based
on a NOEL of 2.5 mg/kg bw in a 2-year rat
study and many effects on the male reproduc-
tive system at ≥ 10 mg/kg bw. Reduced testis
weight, testis atrophy, reduced or absent sper-
matid production, necrotic epididymis, and
atrophy of the prostate were observed with
increasing doses.
Penconazole was evaluated by the JMPR
in 1992 (FAO/WHO 1993b). An ADI of
0–0.03 mg/kg bw was allocated based on a
NOEL of 3 mg/kg bw and reduced testis
weight with atrophic changes at ≥ 17 mg/kg
bw in a 1-year dog study. In long-term stud-
ies, increased prostate weights were observed
in mice at ≥ 9.8 mg/kg bw and in rat testis at
202 mg/kg bw. In a two-generation rat study,
relative ovary weights were increased at
≥ 125 mg/kg bw. At the maternotoxic level
of 500 mg/kg bw, penconazole was also
fetotoxic.
Prochloraz was evaluated by the JMPR
in 2001 (FAO/WHO 2002). An ADI of
0–0.01 mg/kg bw was allocated based on a
NOEL of 1.3 mg/kg bw and liver effects at
≥ 5 mg/kg bw in a 2-year rat study. In a 90-
day rat study, ovary and thyroid weights were
increased in females at ≥ 6 mg/kg bw. In a
90-day dog study, reduced testis and prostate
weights were observed at ≥ 7 mg/kg bw. In a
rat reproduction study, at ≥ 27 mg/kg bw a
tendency to prolonged gestation, increased
total litter losses, smaller litter sizes, and
increased pup mortality was observed. In
trout, 25 nM (9.4 µg/L) prochloraz impaired
the spermatogenesis (Le Gac et al. 2001).
Propiconazole was evaluated by the
JMPR in 1987 (FAO/WHO 1988). An
ADI of 0–0.04 mg/kg bw was allocated
based on a NOEL of 4 mg/kg bw slight
effects on the liver and hematology parame-
ters at ≥ 20 mg/kg bw in a 2-year rat study.
In a rat reproduction study, reduced testis
and epididymis weights in pups were
observed at ≥ 21 mg/kg bw. However, testis
weights of rats were increased at 256 mg/kg
bw in a short-term study.
Tebuconazole was evaluated by the
JMPR in 1994 (FAO/WHO 1995). An ADI
of 0–0.03 mg/kg bw was allocated based on
a NOEL of 3 mg/kg bw and histopathologicREFERENCES
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